|
|
L-ArginineM2
and Nanotechnology
Nanomedicine: Newest Field of Science & Medicine
|
 |
As
of 2006, the genetic, pharmaceutical, nutraceutical, and food
industries have embraced the newest and most promising area
of medicine. Nanomedicine is the science of nanotechnology,
which encompasses futuristic technology.
The
term nanotechnology is used to describe the interdisciplinary
fields of science devoted to the study of nanoscale phenomena
employed in nanotechnology. Spherical nanoparticles are three
dimensions on the nanoscale, i.e., the particle is between
0.1 and 100 nm in each spatial dimension. This
tiny world of chemistry has |
|
spun
into an entire industry of research in which nanoparticles participate
in all facets of medicine, including preventive medicine.
The National
Institutes of Health (NIH) recently announced its Nanomedicine Development
Centers Awards that will share approximately $42-million over five
years. The four advanced centers in nanomedicine are part of the
NIH’s New Pathways to Discovery (www.Nano.gov).
The four centers are: The Center for Protein Folding Machinery at
Baylor College of Medicine; The National Center for Design of Biomimetic
Nanoconductors at the University of Illinois, Urbana-Champaign;
Engineering Cellular Control: Synthetic Signaling and Motility Systems
at the University of California, San Francisco; and the Nanomedicine
Center for Mechanical Biology at Columbia University in New York
(1).
Nanomedicine Development Centers will be established across the
country and will be staffed by multidisciplinary scientific teams,
including biologists, physicians, chemists, physicists, mathematicians,
engineers, and computer scientists. These teams will conduct research
and will train the next generation of students in this new research
area of medical science.
The new $84-million Molecular Foundry on the Lawrence Berkeley National
Laboratory (LBNL) campus in Berkeley, California will allow scientists
to begin making new types of nanoscale material. |
 |
| New
Industrial Revolution |
 |
The
Nanotechnology revolution began in January 2000, when U.S.
President Bill Clinton requested a $227-million increase in
the government’s investment in nanotechnology research
and development. This included a major initiative called the
National Nanotechnology Initiative (NNI) that nearly doubled
America’s budget investment in nanotechnology, bringing
the total invested in nanotechnology to $497-million for the
2001 national budget.
In a written
statement, White House officials said that… “Nanotechnology
is the new frontier and its potential impact is compelling.”
|
|
About
70 percent of the new nanotechnology funding will go to university
research efforts, which will help meet the demand for workers with
nanoscale science and engineering skills. The initiative will also
fund the projects of several governmental agencies, including the
National Science Foundation, the Department of Defense, the Department
of Energy, the National Institutes of Health, NASA and the National
Institute of Standards and Technology.
Nanotechnology is likely to change the way almost everything, including
medicine, computers and cars, are designed and constructed.
Nanotechnology-On-A-Chip
Nanotechnology-on-a-chip is one more dimension of lab-on-a-chip
technology. Biological tests measuring the presence or activity
of selected substances become quicker, more sensitive and more flexible
when certain nanoscale particles are put to work as tags, labels,
or carriers of agents in the body as Edible Computer Chips.
Nanomanufacturing
Manufacturing at the nanoscale involves the industrial application
of nanotechnologies. Nanosize powder particles (nanoparticles) can
be engineered for applications in medicine and biotechnology.
L-ArginineM2 encompasses the first proven technology
for glycoside nanotechnology engineering. The evolution of specific
nanoparticles occurs during the Trutina Dulcem 32-step process (www.TrutinaDulcem.com)
involving the removal of glycosides from organic kiwi fruit. This
technology provides the base for L-ArginineM2. |
|
Nanotechnology: Nutrigenomics
|
|
 |
L-ArginineM2
and Encode™
are currently utilized in the genetic
research field of Nutrigenomics (www.GeneFoundation.com)
as a carrier-mediated-transporter in Sickle Cell disease,
Alzheimer’s disease, Thalassemia, Genetic Polymorphisms,
Dysregulated Arginine Metabolism, and generation of Pituitary
Growth Hormone (GH).
Blood-Brain-Barrier Transport
The components of L-ArginineM2
are manufactured at the nanoscale (patents and
patentspending) which facilitates its ability to cross the
Blood-Brain-Barrier in humans. |
|
Nanotechnology
& the Blood-Brain-Barrier
In its neuroprotective role, the Blood-Brain-Barrier (BBB) blocks
agents from entering the brain. Allowing therapeutic agents to cross
the BBB without allowing dangerous agents access to the delicate
brain-balance is a very intricate process involving many years of
specialized research in Blind Amino Acid Transport Systems and Riders
(BBB Carrier Transport Systems).
The key in Nanoengineering is to biochemically attach a therapeutic
agent combined with a nanoparticle in order to access one of the
four pathways. A nanosized agent is small enough to cross the Blood-Brain-Barrier,
as long as it is a “brain-friendly” agent.
Since a nanoparticle is incredibly small, a delicate and complicated
proprietary process is required to produce L-ArginineM2
and its attendant “brain-friendly” glycosides, which
attach to an L-arginine molecule, thus transporting it safely over
the Blood-Brain-Barrier. Nanoparticles possess a diameter small
enough to penetrate through diminutive capillaries into the cell’s
internal machinery (2) and create a pre-programmed response, thus
the term Edible Computer Chip.
Nanoparticle Paths Of Entry
There are only four distinct paths of entry that allow nanoparticles
to enter the human body. L-ArginineM2 facilitates access
through endothelial-cell-gaps. These gaps allow L-ArginineM2 molecules
to pass into the blood stream, where it is carried throughout the
body, and subsequently passed out of the blood into diff erent tissues.
In the brain, these endothelial cells are packed more tightly together,
due to the existence of zonulae occludentes (tight junctions) between
them, blocking the passage of most molecules. |
|
|
L-Arginine
Transport
Only a specific transport system will allow the amino acid L-arginine
to cross the Blood-Brain-Barrier. L-ArginineM2 plant
glycosides are engineered to cross the Blood-Brain Barrier, providing
a carrier-mediated-transporter for the Blind Amino Acid L-arginine,
with specific function in nanoparticle biostrategy.
Reverse Engineering
L-ArginineM2’s bioengineering process defies reverse-engineering.
It is currently impossible to “copy” or duplicate L-ArginineM2
nanotechnology due to the complexity of the development process.
Clinical Trials
The carrier-mediated-transporter system in L-ArginineM2
has undergone Human In Vivo Clinical Trials in adults, children,
and diabetics, focusing on glycemic response, human adipose tissue
fat-storage, Lipoprotein Lipase (LPL), and blood glucose/insulin
response.
Nano-Future
The future of nanotechnology has vast implications for future generations.
L-ArginineM2 is the first generation of scientific breakthroughs
in nanotechnology and nutrigenomics. The Encode Research Team (www.GeneFoundation.com)
is dedicated to developing and patenting an entire line of low glycemic
nutrigenomic products based on nanotechnology. The Encode Research
Team is planning on introducing the next generation of patented
Edible Computer Chips in 2007, including “Chocolate Computer
Chips”, fat-burning thermogenic energy drinks, low glycemic
candies for children that reduces risk of diabetes, and a sports
drink that actually biochemically improves sports performance.
For more information on Nanotechnology, visit www.EdibleComputerChips.com
and the United States government website www.nano.gov |
| |
|
“Science without religion is lame
and,
conversely, religion without science is blind.
Both are important and should work hand-in-hand”
Albert Einstein
Theory of Relativity
E=MC²
Nobel Prize in Physics
L-ArginineM²
was named in honor of
Albert Einstein
|
|
Albert
Einstein College of Medicine |
|
ALBERT
EINSTEIN COLLEGE OF MEDICINE ENTERS NANOBIO ALLIANCE WITH
UNIVERSITY OF ALBANY COLLEGE OF NANOSCALE SCIENCE & ENGINEERING |
|
|
|
The Albert
Einstein College of Medicine of Yeshiva University
and the College of Nanoscale Science and Engineering (CNSE) of the
University at Albany-State University of New York announced a new
partnership to advance education and research in the cross-disciplinary
fields of nanobiotechnology and nanomedicine.
The
joint research thrusts focus on investigating and optimizing the
interface between the world of biology and the world of nanofabrication
to develop "bio-systems on a chip"
(B-SOCs) for medical and biomedical applications.
The
partnership will bring together the unique expertise and resources
of both institutions to focus on the nanoscale principles and their
application to disease identification and treatment development.
CNSE is based at Albany NanoTech, one
of the largest global centers of nanoscale
scientific research with the most extensive nanotechnology facilities
in the academic world. Albert Einstein College of Medicine, one
of the nation’s top medical schools, receives more than $150
million annually in federal support for innovative medical research.
"We
are excited to be entering into this strategic partnership with
one of the premier medical colleges in the world, particularly as
we ramp up our nanobiotechnology research
and education initiatives," said Alain Kaloyeros, Ph.D., Vice
President and Chief Administrative Officer of CNSE and President
of Albany NanoTech. "Nanotechnology
holds enormous promise for revolutionizing many areas of our lives,
but none more promising than disease identification and treatment.
We look forward to collaborating with the distinguished physicians,
scientists, and students of the Albert Einstein College of Medicine
on some of the most potentially exciting applications for nanoscale
scientific concepts and tools."
These
statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure or
prevent any disease.
|
L-ArginineM2
is backed by a registered federal government Patent, Patents-Pending,
and two decades of L-arginine research |
Illegal
copying of this material is a Federal Offense and violators
will be prosecuted |
|
|
